Vasoactive intestinal peptide — VIP — is a naturally occurring 28-amino-acid neuropeptide studied for anti-inflammatory, immune-modulating, and neuroprotective effects. Here’s what the peer-reviewed evidence shows, and how it fits into peptide protocols reviewed at TelosRX.
What Is VIP Peptide?
VIP stands for vasoactive intestinal peptide — a 28-amino-acid signaling molecule the body produces naturally throughout the nervous system, gut, lungs, and immune tissue. It was first isolated from the small intestine in 1970 and initially named for its ability to dilate blood vessels. Decades of research have since revealed it as one of the most broadly acting immunomodulatory neuropeptides in the human body.
VIP signals through two G-protein-coupled receptors: VPAC1 and VPAC2. These receptors are expressed throughout the central nervous system, lymphoid tissue, lung epithelium, and gastrointestinal tract — which explains why VIP research spans an unusually wide range of physiological systems and conditions.
Compounded VIP is not FDA-approved for any therapeutic indication. Research interest continues to grow, particularly for chronic inflammatory conditions. Any use of compounded VIP is subject to medical approval by a licensed provider who reviews your health history asynchronously before any protocol is issued.
How VIP Works in the Body
VIP functions simultaneously as a neurotransmitter and an immune messenger. When released from nerve endings or certain immune cells, it acts locally on nearby tissue through VPAC1 and VPAC2 receptors — triggering intracellular cascades that shift immune response from pro-inflammatory to anti-inflammatory states.
Key mechanisms identified in published research:
- Cytokine suppression: VIP reduces production of pro-inflammatory cytokines including TNF-α, IL-6, and IL-12 from activated macrophages and dendritic cells
- Regulatory T cell promotion: Studies show VIP promotes differentiation of regulatory T cells (Tregs), which dampen autoimmune and inflammatory activity
- NF-κB inhibition: VIP inhibits the NF-κB signaling pathway — a central regulator of inflammatory gene expression across many cell types
- cAMP activation: Receptor binding elevates intracellular cyclic AMP (cAMP), producing downstream anti-inflammatory signaling
- Neuroprotection: In neural tissue, VIP reduces apoptosis and oxidative stress; preclinical models show protection against neurodegenerative stressors
VIP Peptide Research: Anti-Inflammatory and Autoimmune Evidence
The most established body of VIP research concerns its immune-modulating properties. A foundational review published in the British Journal of Pharmacology and available through the NIH PMC database characterized VIP as “a potent anti-inflammatory factor in both innate and adaptive immunity,” documenting its ability to inhibit pro-inflammatory cytokine production from macrophages, microglia, and dendritic cells.
Animal models of rheumatoid arthritis have shown reduced joint inflammation and cartilage destruction with VIP administration. Research in multiple sclerosis models documented reduced demyelination and inflammatory infiltration. A review on VIP’s role in inflammation and autoimmunity, published in Current Opinion in Investigational Drugs and indexed on PubMed, summarized these findings across multiple autoimmune disease contexts.
The key qualifier: virtually all of this evidence is preclinical. Autoimmune applications have not been validated in large human clinical trials, and VIP is not approved as a treatment for any of these conditions.
VIP Peptide Research: Gut Health and Intestinal Integrity
VIP has long-established roles in gastrointestinal physiology — regulating gut motility, promoting secretory cell function, and protecting intestinal epithelium from inflammatory damage. A 2024 study available via the NIH PMC database found that VIP promoted secretory cell differentiation in intestinal epithelium and significantly reduced radiation-induced intestinal damage in mouse models.
VIP receptors are concentrated in the colon and ileum. In inflammatory bowel disease models, VIP administration has reduced intestinal inflammation through local cytokine suppression. This area of research overlaps with the growing literature on gut-health peptides — for related context, see the TelosRX summary of KPV peptide and gut health research.
VIP Peptide Research: Neuroprotective Evidence
VIP is produced by neurons in the cerebral cortex, hippocampus, and hypothalamus. Preclinical studies in Parkinson’s disease models have found VIP reduced dopaminergic neuron loss. Alzheimer’s model studies have shown improved cognitive markers with VIP treatment.
This is highly preclinical research. No clinical trials have established VIP as an effective approach for neurodegenerative disease in humans. The peer-reviewed literature describes the evidence as “promising preclinical data” and notes that translation to human therapeutic applications remains to be demonstrated.
VIP also plays a well-documented role in circadian rhythm regulation — VIP-expressing neurons in the suprachiasmatic nucleus coordinate the body’s master biological clock and sleep-wake cycles, a function independent of its immune effects.
VIP Peptide Research: Pulmonary and Respiratory Evidence
VIP is a potent bronchodilator — it relaxes airway smooth muscle and reduces pulmonary inflammation. Lung tissue contains a high density of VPAC receptors, and VIP research in respiratory disease has historically included asthma, pulmonary hypertension, and airway inflammatory conditions. Airway dilation improvements have been documented in animal models of respiratory disease.
Research interest in VIP for chronic inflammatory response syndrome (CIRS) has grown, as CIRS involves widespread inflammatory dysregulation that VIP’s immune-modulating properties may theoretically address. This remains an investigational and evolving area without established clinical protocols.
VIP Peptide Research Summary
| Research Area | Model Type | Evidence Stage | Key Finding |
|---|---|---|---|
| Autoimmune disease (RA, MS, Crohn’s) | Animal + in vitro | Preclinical | Reduces TNF-α, IL-6; promotes Tregs |
| Inflammatory bowel disease | Animal + human tissue | Preclinical | Reduces intestinal inflammation markers |
| Gut barrier / epithelial integrity | Animal | Preclinical | Promotes secretory cell differentiation |
| Neuroprotection (Parkinson’s, Alzheimer’s) | Animal | Preclinical | Reduces neuron loss in disease models |
| Pulmonary / bronchodilation | Animal | Preclinical | Airway dilation; reduced lung inflammation |
| Circadian rhythm regulation | Animal + human | Well-established (basic science) | VIP neurons coordinate sleep-wake timing |
VIP Peptide Dosage: What Research Protocols Show
No FDA-approved dosage for VIP exists. No clinical dosage guidelines have been established for human therapeutic use. Figures in circulation come from research protocols, not product labeling or regulatory review.
- Intranasal: Research protocols have used 50–200 mcg administered 1–3 times daily
- Intravenous: Used in some investigational protocols for pulmonary hypertension; requires monitoring for hypotension
- Half-life: VIP degrades rapidly in plasma — approximately 1–2 minutes — which drives the need for frequent dosing or formulations designed to extend activity
Any compounded VIP protocol is subject to evaluation and approval by a licensed provider. At TelosRX, provider review is asynchronous — your health history is assessed before any protocol is issued. Explore the TelosRX peptide research hub for additional compound summaries reviewed by our clinical team.
Side Effects: What Research Documents
Published research on VIP has documented the following effects associated with administration:
- Flushing and vasodilation: A transient warm flushing sensation — the most commonly reported effect, particularly with intravenous use
- Transient hypotension: Blood pressure reduction can occur with systemic administration; significant with IV protocols
- Nasal irritation: Reported with intranasal use at higher doses
- GI effects: Diarrhea and abdominal cramping noted at higher doses in some research subjects
Because VIP is not FDA-approved and long-term human safety data are limited, pre-treatment evaluation by a licensed provider is essential before any use of compounded VIP.
How VIP Compares to Other Anti-Inflammatory Peptides
VIP occupies a distinct mechanistic space relative to other commonly studied anti-inflammatory peptides:
| Peptide | Primary Mechanism | Main Research Areas | Evidence Stage |
|---|---|---|---|
| VIP | VPAC receptor / cAMP / NF-κB inhibition | Autoimmune, gut, neuroprotection, pulmonary | Preclinical, early investigational |
| BPC-157 | Nitric oxide system, growth factor upregulation | Tendon, gut, and muscle repair | Preclinical (animal models) |
| KPV | Melanocortin receptor (MC1R) | IBD, skin inflammation | Preclinical, early clinical |
| LL-37 | Antimicrobial + immunomodulatory | Wound healing, respiratory, infection | Preclinical + early trials |
| TB-500 | Thymosin Beta-4 / actin modulation | Tissue repair, cardiac, neuroprotection | Preclinical |
Frequently Asked Questions About VIP Peptide
What does VIP stand for in peptide research?
VIP stands for vasoactive intestinal peptide — a 28-amino-acid neuropeptide produced naturally throughout the human nervous, immune, and gastrointestinal systems. Despite the abbreviation, its research applications extend far beyond vascular effects into immunology, neuroprotection, and gut biology.
Is VIP peptide FDA-approved?
No. VIP peptide is not FDA-approved for any therapeutic indication in humans. All research on VIP for clinical applications remains in preclinical or early investigational stages. Compounded VIP is not FDA-approved, and any use requires evaluation and approval by a licensed provider before a protocol is issued.
What conditions is VIP peptide studied for?
Published research has examined VIP for autoimmune diseases (rheumatoid arthritis, multiple sclerosis, Crohn’s disease), inflammatory bowel disease, chronic inflammatory response syndrome (CIRS), pulmonary hypertension, and neurodegenerative conditions including Parkinson’s and Alzheimer’s disease models. The evidence base is predominantly preclinical animal and in vitro research.
How is VIP peptide administered?
Research protocols have used intranasal administration (50–200 mcg, 1–3 times daily) and intravenous infusion. VIP degrades rapidly in plasma (half-life approximately 1–2 minutes), which requires frequent dosing or formulations designed to extend activity. Oral administration is not viable due to rapid enzymatic breakdown in the gastrointestinal tract.
What are the side effects of VIP peptide?
Research documents flushing and vasodilation (common with IV use), transient blood pressure reduction, nasal irritation with intranasal administration, and GI effects at higher doses. Long-term safety data in humans are limited given VIP’s research-only status. Pre-treatment provider evaluation is essential.
Can VIP peptide be compounded?
Yes, VIP can be prepared by compounding pharmacies under federal compounding regulations. It is not FDA-approved, and access requires evaluation and approval from a licensed provider. At TelosRX, provider review happens asynchronously — a licensed provider reviews your health history to determine whether a compound is appropriate for your specific situation.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.